Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2010 1
2011 1
2012 2
2013 9
2014 9
2015 6
2016 3
2017 2
2018 2
2019 1
2020 2
2021 7
2022 8
2023 4
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

55 results

Results by year

Filters applied: . Clear all
Page 1
Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu.
Fader AN, Roque DM, Siegel E, Buza N, Hui P, Abdelghany O, Chambers SK, Secord AA, Havrilesky L, O'Malley DM, Backes F, Nevadunsky N, Edraki B, Pikaart D, Lowery W, ElSahwi KS, Celano P, Bellone S, Azodi M, Litkouhi B, Ratner E, Silasi DA, Schwartz PE, Santin AD. Fader AN, et al. Among authors: roque dm. J Clin Oncol. 2018 Jul 10;36(20):2044-2051. doi: 10.1200/JCO.2017.76.5966. Epub 2018 Mar 27. J Clin Oncol. 2018. PMID: 29584549 Clinical Trial.
Randomized Phase II Trial of Carboplatin-Paclitaxel Compared with Carboplatin-Paclitaxel-Trastuzumab in Advanced (Stage III-IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis.
Fader AN, Roque DM, Siegel E, Buza N, Hui P, Abdelghany O, Chambers S, Secord AA, Havrilesky L, O'Malley DM, Backes FJ, Nevadunsky N, Edraki B, Pikaart D, Lowery W, ElSahwi K, Celano P, Bellone S, Azodi M, Litkouhi B, Ratner E, Silasi DA, Schwartz PE, Santin AD. Fader AN, et al. Among authors: roque dm. Clin Cancer Res. 2020 Aug 1;26(15):3928-3935. doi: 10.1158/1078-0432.CCR-20-0953. Epub 2020 Jun 29. Clin Cancer Res. 2020. PMID: 32601075 Free PMC article. Clinical Trial.
Review of Immune Therapies Targeting Ovarian Cancer.
Fan CA, Reader J, Roque DM. Fan CA, et al. Among authors: roque dm. Curr Treat Options Oncol. 2018 Nov 14;19(12):74. doi: 10.1007/s11864-018-0584-3. Curr Treat Options Oncol. 2018. PMID: 30430276 Review.
Oncofertility in gynecologic oncology: an oxymoron?
Roque DM, Santin AD. Roque DM, et al. Future Oncol. 2016 Jul;12(14):1683-6. doi: 10.2217/fon-2016-0167. Epub 2016 May 13. Future Oncol. 2016. PMID: 27173792 No abstract available.
Microtentacle Formation in Ovarian Carcinoma.
Reader JC, Fan C, Ory EC, Ju J, Lee R, Vitolo MI, Smith P, Wu S, Ching MMN, Asiedu EB, Jewell CM, Rao GG, Fulton A, Webb TJ, Yang P, Santin AD, Huang HC, Martin SS, Roque DM. Reader JC, et al. Among authors: roque dm. Cancers (Basel). 2022 Feb 4;14(3):800. doi: 10.3390/cancers14030800. Cancers (Basel). 2022. PMID: 35159067 Free PMC article.
Taxanes: their impact on gynecologic malignancy.
Schwab CL, English DP, Roque DM, Santin AD. Schwab CL, et al. Among authors: roque dm. Anticancer Drugs. 2014 May;25(5):522-35. doi: 10.1097/CAD.0000000000000057. Anticancer Drugs. 2014. PMID: 24300913 Free PMC article. Review.
Updates in therapy for uterine serous carcinoma.
Roque DM, Santin AD. Roque DM, et al. Curr Opin Obstet Gynecol. 2013 Feb;25(1):29-37. doi: 10.1097/GCO.0b013e32835af98d. Curr Opin Obstet Gynecol. 2013. PMID: 23138439 Review.
55 results